Effect of cyclooxygenase inhibitor use on immunotherapy efficacy in non‐small cell lung cancer
Abstract Background A synergistic effect of cyclooxygenase inhibitors (COX‐I) and immune checkpoint inhibitors (ICIs) has been suggested. However, the impact of COX‐I on the efficacy of ICIs is unclear. Here, we aimed to evaluate the relationship between COX‐I use and the efficacy of ICI in patients...
Main Authors: | Osamu Kanai, Takanori Ito, Zentaro Saito, Yuki Yamamoto, Kohei Fujita, Misato Okamura, Masayuki Hashimoto, Koichi Nakatani, Satoru Sawai, Tadashi Mio |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-03-01
|
Series: | Thoracic Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1111/1759-7714.13845 |
Similar Items
-
Retreatment with anti‐PD‐1 antibody in non‐small cell lung cancer patients previously treated with anti‐PD‐L1 antibody
by: Kohei Fujita, et al.
Published: (2020-01-01) -
No need to hesitate: immune‐related neutropenia and thrombocytopenia that improved by corticosteroids
by: Osamu Kanai, et al.
Published: (2021-07-01) -
Small cell lung cancer transformation during immunotherapy with nivolumab: A case report
by: Takuma Imakita, et al.
Published: (2017-01-01) -
The role of cyclooxygenase-1 and cyclooxygenase-2 in lipopolysaccharide and interleukin-1 stimulated enterocyte prostanoid formation
by: W. E. Longo, et al.
Published: (1998-01-01) -
Congenital ventricular septal defects and prenatal exposure to cyclooxygenase inhibitors
by: F. Burdan, et al.
Published: (2006-07-01)